A health worker organises samples collected for further testing at Thanon Mitr Market, amid the spread of the coronavirus disease , in Bangkok, Thailand, January 19, 2021. REUTERS/Chalinee Thirasupa
He said that royally-owned Siam Bioscience had been the most obvious choice of many companies considered for technology transfer from pharmaceutical firm AstraZeneca to make 200 million vaccine doses each year for Thailand and other nations. Thanathorn made his comments on Facebook Live on Monday at an event titled “Royal Vaccine: Who Benefits and Who Doesn’t?”
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
Thailand defends royal company's role in vaccine strategyThailand’s government defended its coronavirus vaccine strategy on Tuesday against opposition criticism that it is too reliant on a company owned by King Maha Vajiralongkorn.
더 많은 것을 읽으십시오 »
A New Covid-19 Battle Plan From Asia: Letting Companies Buy VaccinesWith vaccinations lagging, Indonesia’s government has authorized private companies to acquire Covid-19 vaccines, but some public-health experts say the strategy will steer shots toward the middle-class and wealthy. In Brazil, the same shit will soon be done Make no mistake, the vaccines will always find a way in to the arms of the wealthy before anyone else. Companies will use different vaccines from Government Programme !
더 많은 것을 읽으십시오 »